Lisanti Capital Growth LLC Makes New $7.08 Million Investment in Krystal Biotech, Inc. $KRYS

Lisanti Capital Growth LLC bought a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 19,050 shares of the company’s stock, valued at approximately $7,080,000. Krystal Biotech accounts for about 1.6% of Lisanti Capital Growth LLC’s investment portfolio, making the stock its 12th biggest position.

A number of other hedge funds and other institutional investors also recently made changes to their positions in KRYS. Handelsbanken Fonder AB increased its stake in Krystal Biotech by 58.4% during the 4th quarter. Handelsbanken Fonder AB now owns 105,800 shares of the company’s stock worth $26,084,000 after acquiring an additional 39,000 shares during the period. Fisher Asset Management LLC bought a new stake in shares of Krystal Biotech during the 4th quarter valued at $933,000. Principal Financial Group Inc. lifted its position in shares of Krystal Biotech by 15.6% during the 4th quarter. Principal Financial Group Inc. now owns 165,074 shares of the company’s stock valued at $40,697,000 after acquiring an additional 22,231 shares during the period. William Blair Investment Management LLC grew its holdings in shares of Krystal Biotech by 152.1% during the 4th quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock worth $92,783,000 after purchasing an additional 227,038 shares in the last quarter. Finally, Biondo Investment Advisors LLC grew its holdings in shares of Krystal Biotech by 31.3% during the 4th quarter. Biondo Investment Advisors LLC now owns 68,130 shares of the company’s stock worth $16,797,000 after purchasing an additional 16,245 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Krystal Biotech

In other news, EVP John Charles Thomas sold 1,000 shares of the company’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the transaction, the executive vice president directly owned 1,000 shares in the company, valued at approximately $347,270. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the transaction, the director owned 50,000 shares of the company’s stock, valued at $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 51,642 shares of company stock valued at $16,471,923 in the last quarter. Insiders own 13.10% of the company’s stock.

Krystal Biotech Trading Up 3.2%

KRYS stock opened at $343.34 on Thursday. The stock has a market capitalization of $10.16 billion, a P/E ratio of 43.03 and a beta of 0.53. Krystal Biotech, Inc. has a 12 month low of $136.73 and a 12 month high of $382.54. The firm has a 50-day moving average price of $346.14 and a 200-day moving average price of $300.68.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.70 by $0.09. The company had revenue of $119.22 million for the quarter, compared to analyst estimates of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. As a group, equities analysts predict that Krystal Biotech, Inc. will post 7.68 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on KRYS shares. HC Wainwright raised their price target on Krystal Biotech from $310.00 to $361.00 and gave the stock a “buy” rating in a research report on Tuesday, June 16th. Chardan Capital raised shares of Krystal Biotech to a “strong-buy” rating in a report on Monday, August 3rd. Evercore restated an “outperform” rating and issued a $300.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 5th. Wall Street Zen downgraded shares of Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Finally, Weiss Ratings lowered shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $365.40.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.